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Edited by Irmgard SinningAbstract Non-peptide antagonists of the oxytocin receptor
(OTR) have been developed to prevent pre-term labour. The ben-
zoxazinone-based antagonists L-371,257 and L-372,662 display
pronounced species-dependent pharmacology with respect to
selectivity for the OTR over the V1a vasopressin receptor. Exam-
ination of receptor sequences from diﬀerent species identiﬁed
Ala318 in helix 7 of the human OTR as a candidate discriminator
required for high aﬃnity binding. The mutant receptor
[A318G]OTR was engineered and characterised using ligands
representing many diﬀerent chemical classes. Of all the ligands
investigated, only the benzoxazinone-based antagonists had de-
creased aﬃnity for [A318G]OTR. Molecular modelling revealed
that Ala318 provides a direct hydrophobic contact with a methoxy
group of L-371,257 and L-372,662.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Non-peptide antagonist1. Introduction
The neurohypophysial nonapeptide hormone oxytocin (OT)
increases the frequency and intensity of uterine contraction at
parturition [1,2]. This potent uterotonic action of OT has re-
sulted in the peptide being used clinically to induce and to aug-Abbreviations: GPCR, G-protein-coupled receptor; h, human; r, rat;
bRho, bovine rhodopsin; OT, oxytocin; OTR, oxytocin receptor;
L-366,948, {[cyclo(L-prolyl-D-2-naphthylalanyl-L-isoleucyl-D-pipec-
olyl-L-pipecolyl-D-histidyl)]}; L-368,899, 1-((7,7-dimethyl-2(S)-(2(S)-
amino-4-(methylsulfonyl)butyramido)bicyclo[2.2.1]-heptan-1(S)-yl)-
methyl)sulfonyl-4-(2-methylphenyl)piperazine; L-371,257, 1-{1-[4-[(N-
acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4-yl}-4H-3,1-be-
nzoxazin-2(1H)-one; L-372,662, 1-(1-{4-[1-(2-methyl-1-oxidopyridin-
3-ylmethyl)piperidin-4-yloxyl]-2-methoxybenzoyl}piperidin-4-yl)-1,4-
dihydrobenz[d][1,3]oxazin-2-one; AVP, [arginine8]vasopressin; V1aR,
V1a vasopressin receptor; InsP, inositol phosphate; InsP3, inositol
trisphosphate; OTA, d(CH2)5Tyr(Me)
2Thr4Orn8Tyr(NH2)
9 vasoto-
cin; TM, transmembrane helix
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doi:10.1016/j.febslet.2004.10.108ment labour [3]. Although there is an increase in the
concentration of OT in maternal plasma as pregnancy pro-
gresses, it is not consistently elevated before the onset of la-
bour [4]. Consequently, it appears that it is not changes in
hormone concentration that are critical to parturition but an
increase in uterine sensitivity to OT. This increase in respon-
siveness is achieved through a speciﬁcally timed up-regulation
of oxytocin receptors (OTRs) [5] with OTR mRNA increasing
200-fold in the myometrium at term [6]. As uterine sensitivity
to OT is dictated by the abundance of OTRs available at any
time, peptide [7], and more recently non-peptide [8,9], OTR
antagonists have been developed to block OTRs, to induce
uterine quiescence and thereby prevent the serious problem
of pre-term labour [10].
The OTR has been cloned from a range of species, including
human [6,11,12], it is a Family A (rhodopsin-like) G-protein-
coupled receptor (GPCR) and is a member of the neurohypo-
physial peptide hormone receptor sub-family of GPCRs. In
addition to the OTR, this GPCR sub-family includes the vaso-
pressin receptor subtypes V1a (V1aR), V1b (a.k.a. V3), V2, and
the receptors for vasotocin, isotocin and mesotocin. These
receptors exhibit related pharmacology [13] and possess certain
sequence motifs which are characteristic of the neurohypophy-
sial peptide hormone family of GPCRs [14]. To date, only one
OTR subtype has been cloned, implying that the wide range of
physiological eﬀects of OT are mediated by a single receptor
[2,6]. Signiﬁcant cross-activation can occur however, as OT
and AVP are agonists, albeit weaker, at their counterpart
receptors [13,15].
It has been shown that the OT binding platform involves
extracellular domains of the OTR in addition to the trans-
membrane helical bundle [15–17] which is consistent with
the latest OT:OTR complex molecular models [18]. Deﬁning
non-peptide antagonist recognition and mode of action at
the hOTR would aid future rational drug design. However,
in contrast to OT, binding contacts between non-peptide
antagonists and the hOTR were unknown prior to this
study.
In this study, we use species diﬀerences in the OTR:V1aR
selectivity of benzoxazinone-based non-peptide OTR
antagonists and site-directed mutagenesis, to identify a locus
in transmembrane helix 7 (TM7) of the OTR which pro-
vides a speciﬁc binding epitope required for high aﬃnity
interaction. Furthermore, subsequent molecular model-
ling provided the molecular mechanism underlying our
observations.blished by Elsevier B.V. All rights reserved.
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2.1. Materials
Dulbeccos modiﬁed Eagles medium (DMEM), inositol-free
DMEM, FBS and penicillin/streptomycin were from Gibco (Paisley,
UK); cell culture plastic-ware and restriction enzyme Esp3I were ob-
tained from MBI fermentas (Sunderland, UK). [Tyr2-2,6-3H]OT
([3H]OT), speciﬁc activity 44.5 Ci/mmol and 2-myo-[3H]inositol, spe-
ciﬁc activity 22.3 Ci/mmol were from PerkinElmer (Beaconsﬁeld,
UK). The peptide antagonist d[(CH2)5Tyr(Me)
2Thr4Orn8Tyr
(NH2)
9]VT (OTA) and OT were obtained from Bachem (UK) Ltd
(St. Helens, UK). All other reagents were of analytical grade. The syn-
thetic cyclohexapeptide antagonist L-366,948 [7] and the non-peptide
OTR antagonists L-368,899 [19], L-371,257 [20] and L-372,662 [21]
used in this study were synthesised at the Merck Research Laborato-
ries (West Point, PA).
2.2. Construction of a mutant oxytocin receptor
Mutation of Ala318 in the hOTR was achieved using a PCR ap-
proach. The mutagenic sense oligonucleotide incorporated a single
base change GCCﬁ GGC (bold) for the required Ala318ﬁ Gly318
substitution (underlined) and was 5 0-C-GTC-ATG-CTC-CTG-GGC-
AGC-CTG-AAT-TCC-TGC-TGC-AAC-C-3 0. The PCR cycling con-
ditions were: denaturing, 94 C (1 min); annealing, 60 C (2 min);
extension 72 C (1 min) for 30 cycles followed by extension at 72 C
(7 min). The A318G mutation was subcloned into the mammalian
expression vector pcDNA3.1(-) containing the hOTR using unique
BamHI and Esp3I restriction sites. Mutation was conﬁrmed by auto-
mated ﬂuorescent sequencing (Alta Bioscience, University of Birming-
ham, UK).
2.3. Cell culture and transfection
HEK 293T cells were routinely cultured in DMEM supplemented
with 10% (v/v) FBS, penicillin (100 IU/ml) and streptomycin (100
lg/ml). Cells were maintained in a humidiﬁed 5% (v/v) CO2 incubator
at 37 C. HEK 293T cells were seeded at a density of approximately
5 · 105 cells/100 mm dish, and transfected after 48 h using the calcium
phosphate precipitation method. Brieﬂy, a DNA-calcium phosphate
co-precipitate, containing 10 lg plasmid cDNA for each dish, was pre-
pared 30 min before use. After incubation for 16 h, the media was re-
placed with growth media and cells incubated for 48 h before
harvesting.2.4. Radioligand binding assays
Preparation of HEK 293T cell membranes for subsequent radioli-
gand-receptor binding assays was as described previously [22]. The
protein concentration of membranes was determined using the Pierce
BCA protein assay kit (Pierce Chemical Co.) with BSA as standard.
Binding assays were essentially as described previously [23,24] and con-
tained membranes (200–420 lg), [3H]OT (0.8–2.2 nM) as tracer and
competing ligand at the concentrations indicated, in a ﬁnal volume
of 0.5 ml. Non-speciﬁc binding was deﬁned by unlabeled OT (10
lM). After incubation for 90 min at 30 C to establish equilibrium,
bound and free ligand were separated by sedimentation at 12 000 · g
for 10 min. Membrane pellets were washed and solubilised using Sol-
uene-350 (PerkinElmer) prior to liquid scintillation counting using Hi-
Safe3 (PerkinElmer) as cocktail. Radioligand binding results are
expressed as a percentage of the control (i.e., speciﬁc binding in the ab-
sence of the competing ligand). IC50 values were determined by non-
linear regression after the ﬁtting of Langmuir binding isotherms to
experimentally determined data using the Fig. P. Program (Biosoft,
Milltown, NJ, USA). Dissociation constants (Kd) were calculated from
IC50 values as described [25], using the experimentally determined va-
lue for the aﬃnity of [3H]OT for each construct. Diﬀerences between
the aﬃnity of ligands for wild-type and [A318G]OTR were evaluated
for statistical signiﬁcance by Students t test.
2.5. Measurement of OT-induced accumulation of inositol phosphates
HEK 293T cells were seeded at a density of 2.5 · 105 cell/well in
poly-D-lysine-pre-treated twelve-well plates. OT-induced accumulation
of inositol phosphates was assayed in transfected cells as described pre-
viously [26,27]. Essentially, 24 h post-transfection, medium was re-
placed with inositol-free, DMEM containing 1% (v/v) FBS and 2.0lCi/ml 2-myo-[3H]inositol. After 24 h at 37 C, cells were washed twice
with PBS and incubated with medium containing 10 mM LiCl for 30
min, followed by the addition of OT at the concentration indicated
for a further 30 min. Incubations were terminated by adding 0.5 ml
of 5% (v/v) of perchloric acid containing 1 mM EDTA, and 1 mg/ml
phytic acid hydrosylate. Cells were pelleted at 12 000 · g for 5 min,
supernatants neutralised on ice with 1.2 M KOH, 10 mM EDTA, 50
mM HEPES, and samples loaded onto 0.8 ml Bio-Rad AG1-X8 col-
umns (formate form). After elution of inositol (10 ml water) and glyc-
erophosphoinositol (10 ml, 25 mM NH4COOH containing 0.1 M
HCOOH), a mixed inositol phosphate fraction containing inositol
mono-, bis-, tris-phosphates was eluted (10 ml, 850 mM NH4COOH
containing 0.1 M HCOOH). Radioactivity was determined using
Ultima-Flo AF scintillant (PerkinElmer). EC50 values were determined
by non-linear regression after ﬁtting of logistic sigmoidal curves to the
experimental data.
2.6. Molecular modelling of the hOTR
An hOTR homology model was generated from the ground-state
crystal structure of bovine rhodopsin (bRho) determined at 2.8 A˚ res-
olution [28] (PDB accession numbers 1F88, 1HZX). An alignment be-
tween bRho and the hOTR was made with Fasta followed by hand
adjustment. Overall sequence similarity between the hOTR and rho-
dopsin is 48% when identical residues and conserved substitutions
are included. The model was generated using the homology modelling
module in InsightII from MSI. Energy minimisation of the receptor
model was carried out to relieve steric repulsion of the side-chains,
while Ca of the transmembrane helices were constrained so that the
backbone of the TM regions remained unchanged. The loops were fur-
ther reﬁned with high temperature molecular dynamic simulations. A
database of 100 diﬀerent conformations of each of the non-peptide
antagonists L-371,257, L-372,662 and L-368,899 was prepared which
incorporated geometric constraints for the position of atoms within
the molecule, such as bond length and bond angle, together with al-
lowed torsion angles. The conformations generated were then energy
minimised. The ligand binding site of the OTR was deﬁned as the re-
gion within 10 A˚ of the position rhodopsin-bound retinal would occu-
py when projected onto the OTR structure, a position supported by
empirical site-directed mutagenesis data [29]. A grid map was gener-
ated which described the energetics of the binding site. Each of the dif-
ferent conformations was docked into the binding site using the
docking program FLOG (ﬂexible ligand on a grid) with reference to
the grid map. Approximately thirty high-ranking binding conforma-
tions of each compound were visually inspected. Poses exhibiting steric
clashes with the receptor were discounted, whereas those possessing
reasonable van der Waals contacts and good polar interactions were
considered candidates. When each of the candidate poses of the
docked ligands was compared for all of the compounds investigated,
a consensus conformation emerged for L-371,257 and L-372,662. In
contrast, L-368,899 which possesses a bulky group and a sulfate in
the centre of the molecule, did not adopt a conformation similar to this
consensus conformation.3. Results
3.1. Pharmacological characterisation of hOTR constructs
The structurally-related non-peptide oxytocin antagonists L-
371,257 and L-372,662 (Fig. 1) are capable of binding to both
OTRs and V1aRs [20,21]. However, the interaction of L-
371,257 and L-372,662 with these two receptors diﬀers in one
important aspect. Although these ligands bind with high aﬃn-
ity to the OTR from both human and rat, they exhibit species-
speciﬁc pharmacology with respect to the V1aR. For example,
L-371,257 displays high aﬃnity for the rat V1aR (Kd = 3.7 nM)
but low aﬃnity for the human V1aR (Kd = 3200 nM [20]). This
implies that residues that are conserved in the hOTR, rOTR
and rV1aR but which are substituted in the hV1aR are candi-
dates for providing a high aﬃnity binding epitope for L-
371,257 and L-372,662. Comparison of the sequence of TM7
of the hOTR, rOTR, hV1aR and rV1aR revealed a high degree
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Fig. 1. Structure of OTR antagonists. The structures of antagonists used in this study are shown. (A) L-366,948; (B) L-368,899; (C) L-371,257 and
(D) L-372,662.
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absolute identity within this helix. It was noted (Fig. 2), that
residue 7.42 (using the notation proposed for GPCRs by Bal-
lesteros and Weinstein [30]) is an alanyl in the hOTR, rOTR
and the rV1aR (Ala
318, Ala317, Ala342, respectively) but is re-
placed by a glycyl (Gly337) in the hV1aR, and is therefore a can-
didate for providing a binding contact required for high
aﬃnity binding of the non-peptide antagonists L-371,257 and
L-372,662.
To investigate the role of residue 7.42 in non-peptide ligand
recognition, a mutant hOTR was engineered in which Ala318 in
the hOTR was substituted by Gly318 ([A318G]OTR). The con-     ec3   TM7 
(7.42)
TM6 
        (6.48) (6.51) 
A
B
Fig. 2. Alignment of the TM7 helix of the OTR and V1aR from human
(h) and rat (r). Residues absolutely conserved in all four receptors are
shown in capital letters. Sequences cited were obtained from Swissprot
PDB and GenEMBL. Panel A: the distal segment of the third
extracellular loop (e3) is shown with the TM7 helix (boxed) in each
case. The position of residue (7.42) is indicated by an arrow and bold
typeface. Panel B: the TM6 helix (boxed) is shown in each case. The
position of residues Phe (6.51) and Trp (6.48) is indicated by an arrow
and bold typeface.struct [A318G]OTR was expressed in HEK 293T cells, phar-
macologically characterised and compared to wild-type
hOTR. Both receptors were expressed at the same level of
0.2–0.5 pmol/mg protein. A range of ligands representing very
diverse structural classes was employed for this pharmacolog-
ical characterisation (Fig. 1). These were, (i) the natural pep-
tide agonist OT; (ii) the peptide antagonist (CH2)5Tyr(Me)
2
Thr4Orn8Tyr9NH2 (OTA); (iii) the synthetic cyclohexapeptide
antagonist L-366,948 (Fig. 1A) [7]; (iv) the camphor-based
non-peptide antagonist L-368,899 (Fig. 1B) [19,31] and (v)
the benzoxazinone-based non-peptide antagonists L-371,257
(Fig. 1C) [20] and L-372,662 (Fig. 1D) [21]. Competition radi-
oligand binding curves were determined for each ligand bind-
ing to [A318G]OTR and to the wild-type hOTR (Fig. 3). The
Kd values are presented in Table 1, corrected for radioligand
occupancy. The aﬃnity of OT and the three classes of antago-
nist represented by OTA, L-366,948 and L-368,899 were un-
changed by the Ala318 to Gly318 substitution. In contrast,
both of the benzoxazinone-based non-peptide antagonists (L-
371,257 and L-372,662) were aﬀected (Fig. 3E and F) and
exhibited a 6–12-fold lower aﬃnity for [A318G]OTR com-
pared to wild-type hOTR (Table 1). The wild-type binding
characteristics of [A318G]OTR with respect to the natural
agonist and three diﬀerent chemical classes of antagonist (both
peptide and non-peptide) was strong evidence that the overall
folding of the receptor had not been perturbed by the
Ala318ﬁ Gly318 (7.42) mutation in TM7. Further evidence
that wild-type tertiary structure was preserved in [A318G]OTR
was provided by the observation that the dose–response rela-
tionship for OT-induced inositol phosphates accumulation
by [A318G]OTR was wild-type (Fig. 4).3.2. Molecular modelling of non-peptide antagonists docked to
hOTR
An homology model of the hOTR was constructed utilising
the recently solved crystal structure of bRho [28]. Both of these
receptors belong to the Family A class of GPCRs and exhibit a
series of highly conserved signature residues in the transmem-
brane regions (shown in bold in Fig. 5) which are characteristic
of this family of receptors. The alignment preserves the relative
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Fig. 3. Pharmacological characterisation of wild-type hOTR and [A318G]OTR. Competition radioligand binding studies using HEK 293T cells
expressing either the wild-type OTR (s) or the [A318G]OTR mutant (d) were performed using (A) OT; (B) peptide antagonist, OTA; (C)
cyclopeptide antagonist, L-366,948; (D) the camphor-based non-peptide antagonists L-368,899 and the benzoxazinone-based non-peptide
antagonists L-371,257 and L-372,662, (E) and (F), respectively. Data shown are the means ± S.E.M. of at least three separate experiments each
performed in triplicate. Values are expressed as % speciﬁc binding where non-speciﬁc binding was deﬁned by OT (10 lM). A theoretical Langmuir
isotherm competition curve was ﬁtted to the experimental data as described in Section 2.
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peptide ligands were then docked, as described in Section 2.
From the binding positions of L-371,257, L-372,662 and L-
368,899 presented in Fig. 6A, B and C, respectively, it is appar-
ent that all of these compounds occupy a similar region within
the transmembrane helical bundle of the hOTR. In the wild-
type hOTR, Ala318 (7.42) is located in direct hydrophobic
contact with the methoxy group protruding from the benzene
moiety which is central to the structure of L-371,257 (Fig. 6A).
It can be seen that Ala318 (7.42) straddles two aromatic rings,
with Phe291 (6.51) and Trp288 (6.48) positioned above and be-
low, respectively. This orientation enables these two residues in
TM6 to make p-stacking interactions with the same central
benzene ring of L-371,257 contacted by Ala318. From thismolecular arrangement it is apparent that mutation of the
Ala318 in the construct [A318G]OTR would result in the loss
of the hydrophobic contact between the methoxy of L-
371,257 and residue 7.42 of the receptor (Fig. 6A). Further-
more, in the absence of the Ala318 to inﬂuence local side-chain
orientation, there would be free rotation of the side-chains of
Phe291 and Trp288, resulting in a corresponding decrease in
p-stacking interactions with the benzene group of L-371,257.
Modiﬁcation of the acetylpiperidine terminus of L-371,257
by pyridine N-oxide resulted in the compound L-372,662
(Fig. 1D). From the overlay presented in Fig. 6B it is apparent
that both L-371,257 and L-372,662 establish very similar inter-
actions when bound to the hOTR. Consequently, the role of
Ala318 and the molecular ramiﬁcations of the A318G mutation
Table 1
Pharmacological proﬁle of wild-type hOTR and [A318G]OTR
Ligand Binding aﬃnities Kd (nM)
OTR A318G
OT 1.4 ± 0.5 1.4 ± 0.3
OTA 1.7 ± 0.5 2.4 ± 0.4
L-366,948 4.0 ± 0.7 5.4 ± 0.8
L-368,899 14 ± 1.9 13 ± 2.2
L-371,257 12 ± 0.8 72 ± 13 (4)***
L-372,662 5.8 ± 0.4 73 ± 23 (4)***
Expression Bmax
(pmoles/mg protein)
0.5 ± 0.2 0.2 ± 0.1
***Signiﬁcantly diﬀerent from wild-type OTR, P < 0.001.
[3H]OT was used as tracer in competition radioligand binding assays.
Dissociation constants (Kd) were calculated from IC50 values, cor-
rected for radioligand occupancy. All values shown are the means
± S.E.M. of three separate experiments, except where n = 4 is indi-
cated, each performed in triplicate.
EC50 (nM)
    OTR = 1.7 ± 0.6 
 A318G = 1.9 ± 0.6
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Fig. 4. Intracellular signalling by wild-type hOTR and [A318G]OTR.
OT-induced accumulation of InsP–InsP3 in HEK 293T cells transfec-
ted with either wild-type OTR (s) or A318G mutant (d). Data shown
are the means ± S.E.M. of three separate experiments performed in
triplicate. Values are expressed as % maximum stimulation induced by
OT at the stated concentrations.
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moiety of L-372,662 is accommodated within an hydrophobic
pocket formed by the residues Val88 and Val93 of TM2 in con-
junction with Ile49 and Ala53 of TM1 while the N-oxide is in
close contact with Ser322 of TM7 and forms a hydrogen bond
(Fig. 6B). This additional interaction may explain why the
aﬃnity of L-372,662 for the hOTR is slightly higher than that
of L-371,257 (Table 1). The camphor-based non-peptide
antagonist L-368,899 also binds in the vicinity of Ala318,
Phe291 and Trp288. However, in this instance there is no direct
hydrophobic contact between the ligand and Ala318 and the
interaction of Phe291 and Trp288 with L-368,899 is less optimal
than with L-371,257 due to the lack of aromaticity and the
overall diﬀerence in conformation (Fig. 6C). The absence of
a binding contact between L-368,899 and Ala318 explains
why, in marked contrast to the benzoxazinone-based antago-Fig. 5. Alignment of the sequence of bRho and the hOTR. Transmembrane (
loops are shown in yellow and white, respectively. Residue number is indicat
Family A GPCRs are indicated in bold and cysteines forming a disulphide bnists L-371,257 and L-372,662, this camphor-based antagonist
binds with high aﬃnity to both wild-type hOTR and the mu-
tant construct [A318G]OTR.4. Discussion
The non-peptide ligand L-371,257 was developed as an OTR
antagonist from the structure of the V1aR non-peptide antag-
onist OPC-21268 [32] as the lead compound [9,20]. Subsequent
characterisation revealed that L-371,257 exhibits species-
speciﬁc pharmacology, which has profound ramiﬁcations withTM) regions are shown in green, extracellular (ec) and intracellular (ic)
ed on the right-hand side of the ﬁgure. Residues conserved throughout
ond in Family A GPCRs are indicated by +.
Fig. 6. Molecular model of the hOTR docked with non-peptide antagonists. Amino acid side-chains are shown in white and are labelled in yellow
together with the residue number. In each case, only key residues cited in the text are illustrated for clarity. (A) Interaction of L-371,257 with Ala318
(7.42), Phe291 (6.51) and Trp288 (6.48). The contacts formed when the benzoxazinone-based non-peptide antagonist L-371,257 is bound to the hOTR
are indicated by double-headed arrows. (B) Overlay of L-371,257 (green) and L-372,662 (cyan) docked to the hOTR revealing the high degree of
overlap between the binding position of these structurally-related ligands and the common role of Ala318. (C) Although the camphor-based non-
peptide antagonist L-368,899 binds in a similar position in the hOTR as the benzoxazinone-based non-peptide antagonists L-371,257 and L-372,662
it does not make the same binding contacts and does not involve Ala318. For further details refer to the text.
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L-371,257 is slightly V1aR-selective in the rat (5-fold) but in
marked contrast, it is profoundly OTR-selective in the human
(865-fold) [8,20]. Given the therapeutic potential of L-371,257,
the compound has been subjected to extensive and systematic
chemical modiﬁcation aimed at improving its pharmacological
characteristics as a putative drug for the treatment of pre-term
labour. One such series, incorporating various pyridine N-
oxide groups at the acetylpiperidine terminus of L-371,257,generated L-372,662 which exhibited increased potency, im-
proved pharmacokinetics and excellent bioavailability [21].
The pronounced species-dependent pharmacology with respect
to OTR:V1aR selectivity was exhibited by both of the benzox-
azinone-based compounds L-371,257 and L-372,662. Such spe-
cies-selectivity is not restricted to non-peptide ligands however,
as the phenomenon has also been reported for a range of neu-
rohypophysial hormone receptor peptide ligands [33–35]. Cor-
relating the pharmacological characteristics of L-371,257 and
S.R. Hawtin et al. / FEBS Letters 579 (2005) 349–356 355L-372,662 with sequence homology between OTR and V1aR
from human and rat, identiﬁed Ala318 (7.42) in the hOTR as
a candidate for providing a species-speciﬁc binding epitope
for these non-peptide antagonists.
The binding aﬃnity of L-372,662 was decreased by the
Ala318ﬁ Gly318 mutation in a very similar manner to the lead
compound L-371,257 (Fig. 3E and F), despite the structural
diﬀerences (Fig. 1). This is entirely consistent with our molec-
ular model, as the features of L-371,257 which are shown in
Fig. 6A to be important for interacting with the receptor in
the L-371,257:hOTR complex are retained in L-372,662 (Fig.
1). Consequently, the model predicted that Ala318 (7.42) con-
tributed to high aﬃnity binding of both L-371,257 and L-
372,662 to the hOTR (Fig. 6B). Although Ala318 was required
for high aﬃnity binding of benzoxazinone-based non-peptide
antagonists, it did not provide binding epitopes for non-pep-
tide antagonists in general (Fig. 3 and Table 1). Modelling of
L-371,257 and L-372,662 plus another chemically-unrelated
non-peptide antagonist L-368,899, docked to the hOTR pro-
vided the molecular explanation for these observations (Fig.
6). Our data indicate an interaction between the benzoyl meth-
oxy group of the ligand L-371,257 and Ala318 (7.42) of the
hOTR. This proposed interaction of Ala318 with a methoxy
group in the ligand is supported experimentally. Removal of
the methoxy group from the ligand, to generate the des-meth-
oxy analogue of L-371,257, resulted in a 4-fold reduction in
aﬃnity for the hOTR [20]. This is almost identical to the 6-fold
decrease in aﬃnity of L-371,257 for the hOTR resulting from
the A318G mutation (Table 1). Taken together these two
observations are supportive of a role for Ala318 (7.42) in bind-
ing L-371,257. Although Ala318 (7.42) provides a molecular
discriminator underlying species-selective binding of benzoxaz-
inone-based antagonists with OTRs, this would obviously be
only one of many contacts between the docked ligand and
the receptor, the majority of which do not contribute to spe-
cies-speciﬁc pharmacology.
Ala318 did not have a role in binding peptides (agonist or
antagonist), nor in the OT-induced transition from the ground
state of the receptor (R) to the active conformation (R*) as
intracellular signalling of [A318G]OTR was wild-type (Fig.
4). It has recently been reported by two groups independently,
that high aﬃnity binding of the non-peptide antagonist OPC-
21268 to the V1aR also required an alanyl in TM7 at residue
7.42 [36,37], whereas the binding of the non-peptide antagonist
SR 49059 to the V1aR did not [36]. The proposed orientation
of OPC-21268 binding to the hV1aR [38] however, is diﬀerent
from that of L-371,257 docked to the hOTR (Fig. 6A). With
respect to the binding of the benzoxazinone-based antagonists
L-371,257 and L-372,662 to the V1aR, the Ala (7.42) is pre-
served in the rat receptor which exhibits high aﬃnity, but is re-
placed by a Gly (7.42) in the human receptor which exhibits
low binding aﬃnity (Fig. 2A). Furthermore, the aromatic
side-chains of Phe (6.51) and Trp (6.48) in TM6, which contact
the central benzene ring of L-371,257 and straddle the Ala
(7.42) in the hOTR, are also conserved in V1aRs (Fig. 2B).
Consequently, key features identiﬁed for high aﬃnity binding
of benzoxazinone-based antagonists to the hOTR are also
present in the rV1aR which also exhibits high aﬃnity binding
of L-371,257 and L-372,662.
It is noteworthy that when docked into the hOTR binding
site, L-371,257 and L-372,662 reside in a similar location in
the TM helical bundle as the retinal binding site in bRho. In-deed, the Ala318 (7.42) which contributes to the high aﬃnity
binding of these compounds is only one residue higher in the
TM7 helix than the 11-cis-retinal covalent attachment site in
rhodopsin (Lys296 (7.43)).
In conclusion, this study provides a plausible molecular
model for the species-dependent OTR:V1aR selectivity exhib-
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